Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
MD

NASDAQ · MDXH

MDxHealth SA Ordinary Shares

Healthcare · Medical - Diagnostics & Research

$0.68

Up+$0.03 (+4.23%)

Updated Sep 12, 2026, 12:16 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
168.79M
P/E ratio
-5.04
Dividend yield
0.00%
52-week range
$0.40 – $3.56
Volume
283.4K
Avg. volume
210.84K

Price performance

MDXH price history

1M range · 20 trading sessions · Daily adjusted prices

MDXH closed at $0.68 after 20 trading sessions, up 46.32% for the selected period.

Last close
$0.68
Period change
+46.32%
Period low
$0.46
Period high
$0.86
Daily close
View OHLC price history
MDXH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$0.695$0.6995$0.667$0.676283.4K
Sep 9, 2026$0.72$0.726$0.691$0.69289.38K
Sep 8, 2026$0.7499$0.75$0.70$0.7135329.98K
Sep 4, 2026$0.719$0.7499$0.7123$0.7484271.6K
Sep 3, 2026$0.7307$0.7349$0.703$0.7262169.61K
Sep 2, 2026$0.72$0.7499$0.6907$0.71207.42K
Sep 1, 2026$0.71$0.74$0.71$0.7203197.03K
Aug 31, 2026$0.71$0.735$0.71$0.7202211.09K
Aug 28, 2026$0.7211$0.7499$0.68$0.7207277.13K
Aug 27, 2026$0.756$0.79$0.7211$0.7215270.93K
Aug 26, 2026$0.80$0.80$0.7401$0.7561192.53K
Aug 25, 2026$0.7413$0.80$0.7266$0.7888430.58K
Aug 24, 2026$0.75$0.77$0.72$0.7413401.87K
Aug 21, 2026$0.721$0.75$0.7127$0.7431398.14K
Aug 20, 2026$0.779$0.7899$0.72$0.72545.34K
Aug 19, 2026$0.7708$0.8279$0.7518$0.7591796.7K
Aug 18, 2026$0.83$0.91$0.745$0.75122.65M
Aug 17, 2026$0.7137$0.93$0.7099$0.855610.65M
Aug 14, 2026$0.6075$1.13$0.5807$0.808326.59M
Aug 13, 2026$0.46$0.4911$0.4451$0.4628.27M

Latest MDXH news

The latest Smart Investors Daily articles mentioning MDXH.

Stock researchCompany · Overview

MDXH research

Overview

Company profile and research snapshot.

Company profile

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
MDXH recent ratings
DateFirmRatingTarget
Aug 21, 2026BTIGBuy—
Aug 14, 2026Lake StreetBuy—
May 14, 2026TD CowenBuy—
May 14, 2026BTIGBuy—
May 14, 2026Lake StreetBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 5, 2026

MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution

MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By